CA2077265A1
(en)
*
|
1991-01-10 |
1992-07-11 |
Andrew Young |
Amylin activity assays
|
HU222249B1
(en)
*
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
|
DE69221725T2
(en)
*
|
1991-05-24 |
1997-12-18 |
Amylin Pharmaceuticals, Inc., San Diego, Calif. |
COMPOSITION CONTAINING AMYLIN OR AMYLINANALOG, WHICH ALSO CONTAINS INSULIN FOR THE TREATMENT OF ANOREXIA AND RELATED CONDITIONS
|
US5814600A
(en)
*
|
1991-05-24 |
1998-09-29 |
Amylin Pharmaceuticals Inc. |
Method and composition for treatment of insulin requiring mammals
|
ATE205854T1
(en)
*
|
1991-11-19 |
2001-10-15 |
Amylin Pharmaceuticals Inc |
PEPTIDES AS AMYLIN AGONISTS AND THEIR USE
|
CZ69596A3
(en)
*
|
1993-09-07 |
1997-06-11 |
Amylin Pharmaceuticals Inc |
Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
|
GB9409496D0
(en)
|
1994-05-12 |
1994-06-29 |
London Health Ass |
Method for improving glycaemic control in diabetes
|
US5763200A
(en)
*
|
1995-05-12 |
1998-06-09 |
Biomeasure, Incorporated |
Inhibition of amylin release
|
US6143718A
(en)
*
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
US5677279A
(en)
*
|
1996-12-16 |
1997-10-14 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating pain with amylin or agonists thereof
|
US7312196B2
(en)
*
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US7101853B2
(en)
|
1997-05-06 |
2006-09-05 |
Amylin Pharmaceuticals, Inc. |
Method for treating or preventing gastritis using amylin or amylin agonists
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
WO2000078805A1
(en)
*
|
1999-06-18 |
2000-12-28 |
Protemix Corporation Limited |
Peptide having preptin functionality
|
EP1251867A4
(en)
|
2000-02-04 |
2004-12-08 |
Unigene Lab Inc |
Nasal calcitonin formulations
|
WO2002043566A2
(en)
*
|
2000-11-28 |
2002-06-06 |
Baum Martin G |
Devices and methods for treating low blood sugar levels
|
US20030208113A1
(en)
*
|
2001-07-18 |
2003-11-06 |
Mault James R |
Closed loop glycemic index system
|
US20040038861A1
(en)
*
|
2001-11-26 |
2004-02-26 |
Cooper Garth J. S. |
Methods and compositions for normalizing lipid levels in mammalian tissues
|
US20040009976A1
(en)
*
|
2002-04-30 |
2004-01-15 |
Kumiko Takeuchi |
Hypoglycemic imidazoline compounds
|
US20040142393A1
(en)
*
|
2002-08-01 |
2004-07-22 |
Cooper Garth James Smith |
Methods of use of compounds with preptin function
|
US8168233B2
(en)
*
|
2002-10-18 |
2012-05-01 |
Amylin Pharmaceuticals, Inc. |
Treatment of pancreatitis with amylin
|
CA2509755A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
US7655618B2
(en)
*
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
RU2360671C2
(en)
*
|
2003-07-01 |
2009-07-10 |
Эссентис Аб |
Application of alpha-ketoglutaric acid for treatment of undernutrition or condition with high-glucose plasma level
|
US7591801B2
(en)
|
2004-02-26 |
2009-09-22 |
Dexcom, Inc. |
Integrated delivery device for continuous glucose sensor
|
CN1961000B
(en)
|
2004-02-11 |
2011-05-04 |
安米林药品公司 |
Hybrid polypeptides with selectable properties
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
WO2009048462A1
(en)
|
2007-10-09 |
2009-04-16 |
Dexcom, Inc. |
Integrated insulin delivery system with continuous glucose sensor
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
CA2597649A1
(en)
*
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
US7879794B2
(en)
|
2005-03-31 |
2011-02-01 |
Amylin Pharmaceuticals, Inc. |
Methods for controlling binge eating disorders
|
CA2617649A1
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
BRPI0614649A2
(en)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
hybrid polypeptides with selectable properties
|
JP5312054B2
(en)
|
2006-03-15 |
2013-10-09 |
ノボ・ノルデイスク・エー/エス |
Mixture of amylin and insulin
|
US20090181890A1
(en)
*
|
2006-03-31 |
2009-07-16 |
Amylin Pharmaceuticals , Inc. |
Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
|
WO2007114838A1
(en)
|
2006-03-31 |
2007-10-11 |
Amylin Pharmaceuticals, Inc. |
Amylin and amylin agonists for treating psychiatric diseases and disorders
|
US8536120B2
(en)
*
|
2006-04-28 |
2013-09-17 |
The Administrators Of The Tulane Educational Fund |
Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
US20080076721A1
(en)
*
|
2006-09-25 |
2008-03-27 |
Sal Abraham |
Use of branched chain fatty acid amino acid salts and compositions thereof
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
EP2203741B1
(en)
|
2007-10-25 |
2023-05-10 |
Dexcom, Inc. |
Systems and methods for processing sensor data
|
WO2010091122A1
(en)
|
2009-02-03 |
2010-08-12 |
Amunix, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
US9724381B2
(en)
|
2009-05-12 |
2017-08-08 |
The Administrators Of The Tulane Educational Fund |
Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
|
AU2010258898B8
(en)
|
2009-06-08 |
2015-02-05 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
SG11201707286UA
(en)
|
2015-03-18 |
2017-10-30 |
Zealand Pharma As |
Amylin analogues
|
US10071140B2
(en)
|
2016-09-09 |
2018-09-11 |
Zealand Pharma A/S |
Amylin analogues
|
CN110366424B
(en)
|
2016-12-27 |
2024-05-24 |
阿道恰公司 |
Composition in the form of an injectable aqueous solution comprising an amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
|
PL3658115T3
(en)
|
2017-07-27 |
2022-08-08 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
|
FR3082426A1
(en)
|
2018-06-14 |
2019-12-20 |
Adocia |
COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AT LEAST HUMAN INSULIN A21G AND A PRANDIAL ACTION GLUCAGON SUPPRESSOR
|
FR3083089A1
(en)
|
2018-06-29 |
2020-01-03 |
Adocia |
PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
|
FR3083086A1
(en)
|
2018-06-29 |
2020-01-03 |
Adocia |
COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
|
CA3084699A1
(en)
|
2017-12-07 |
2019-06-13 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analog and a co-polyamino acid
|
US20190275108A1
(en)
|
2017-12-07 |
2019-09-12 |
Adocia |
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
|
EP3723728A1
(en)
|
2017-12-07 |
2020-10-21 |
Adocia |
Injectable solution with a ph of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals
|
CN111565710A
(en)
|
2017-12-07 |
2020-08-21 |
阿道恰公司 |
Composition in the form of an injectable aqueous solution comprising an amylin, an amylin receptor agonist or an amylin analog, and a copolyaminoacid
|
SG11202005322RA
(en)
|
2017-12-07 |
2020-07-29 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
|
FR3083085B1
(en)
|
2018-06-29 |
2020-10-02 |
Adocia |
COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
|
FR3084586B1
(en)
|
2018-08-03 |
2020-11-06 |
Adocia |
COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
|
IL292863A
(en)
|
2019-11-13 |
2022-07-01 |
Amunix Pharmaceuticals Inc |
Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
|
EP3915572A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
EP3915571A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|